FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057201731> ?p ?o ?g. }

• W2057201731 endingPage "365" @default.
• W2057201731 startingPage "356" @default.
• W2057201731 abstract "Summary To test the safety and activity of 5‐aza‐2′‐deoxycytidine (decitabine) in patients with relapsed/refractory acute lymphocytic leukaemia ( ALL ), we conducted a phase 1 study with two parts: administering decitabine alone or in combination with Hyper‐ CVAD (fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high‐dose methotrexate and cytarabine). Patients participated in either part of the study or in both parts sequentially. In the initial part, decitabine was administered intravenously at doses of 10–120 mg/m 2 per d for 5 d every other week in cycles of 28 d. In the combination part, patients were treated on the first 5 d of Hyper‐ CVAD with intravenous decitabine at 5–60 mg/m 2 per d. A total of 39 patients received treatment in the study: 14 in the first part only, 16 sequentially in both parts and 9 in the second part only. Decitabine was tolerated at all doses administered, and grade 3 or 4 toxic effects included non‐life‐threatening hepatotoxicity and hyperglycaemia. Induction of DNA hypomethylation was observed at doses of decitabine up to 80 mg/m 2 . Some patients who had previously progressed on Hyper‐ CVAD alone achieved a complete response when decitabine was added. Decitabine alone or given with Hyper‐ CVAD is safe and has clinical activity in patients with advanced ALL ." @default.
• W2057201731 created "2016-06-24" @default.
• W2057201731 creator A5000750846 @default.
• W2057201731 creator A5006104041 @default.
• W2057201731 creator A5033546842 @default.
• W2057201731 creator A5036349678 @default.
• W2057201731 creator A5038307470 @default.
• W2057201731 creator A5042667629 @default.
• W2057201731 creator A5049385583 @default.
• W2057201731 creator A5055045706 @default.
• W2057201731 creator A5060055306 @default.
• W2057201731 creator A5061026876 @default.
• W2057201731 creator A5062979200 @default.
• W2057201731 creator A5070904381 @default.
• W2057201731 creator A5077963154 @default.
• W2057201731 creator A5090435894 @default.
• W2057201731 date "2014-07-26" @default.
• W2057201731 modified "2023-10-15" @default.
• W2057201731 title "Safety and clinical activity of 5-aza-2′-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia" @default.
• W2057201731 cites W1862517694 @default.
• W2057201731 cites W1966474816 @default.
• W2057201731 cites W1980646204 @default.
• W2057201731 cites W1984807040 @default.
• W2057201731 cites W1988466148 @default.
• W2057201731 cites W2041175983 @default.
• W2057201731 cites W2043244590 @default.
• W2057201731 cites W2053315780 @default.
• W2057201731 cites W2053747212 @default.
• W2057201731 cites W2054383376 @default.
• W2057201731 cites W2061216977 @default.
• W2057201731 cites W2069803537 @default.
• W2057201731 cites W2070685259 @default.
• W2057201731 cites W2071420568 @default.
• W2057201731 cites W2072959752 @default.
• W2057201731 cites W2074641381 @default.
• W2057201731 cites W2081391009 @default.
• W2057201731 cites W2084021611 @default.
• W2057201731 cites W2086990980 @default.
• W2057201731 cites W2096358100 @default.
• W2057201731 cites W2096577052 @default.
• W2057201731 cites W2096804956 @default.
• W2057201731 cites W2097587005 @default.
• W2057201731 cites W2098236778 @default.
• W2057201731 cites W2102085111 @default.
• W2057201731 cites W2106658124 @default.
• W2057201731 cites W2107648723 @default.
• W2057201731 cites W2109895173 @default.
• W2057201731 cites W2113231429 @default.
• W2057201731 cites W2115499099 @default.
• W2057201731 cites W2131793839 @default.
• W2057201731 cites W2142139678 @default.
• W2057201731 cites W2145338511 @default.
• W2057201731 cites W2145750252 @default.
• W2057201731 cites W2163542527 @default.
• W2057201731 cites W2163710445 @default.
• W2057201731 cites W4232414730 @default.
• W2057201731 doi "https://doi.org/10.1111/bjh.13050" @default.
• W2057201731 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4198465" @default.
• W2057201731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25066676" @default.
• W2057201731 hasPublicationYear "2014" @default.
• W2057201731 type Work @default.
• W2057201731 sameAs 2057201731 @default.
• W2057201731 citedByCount "35" @default.
• W2057201731 countsByYear W20572017312015 @default.
• W2057201731 countsByYear W20572017312016 @default.
• W2057201731 countsByYear W20572017312017 @default.
• W2057201731 countsByYear W20572017312018 @default.
• W2057201731 countsByYear W20572017312019 @default.
• W2057201731 countsByYear W20572017312020 @default.
• W2057201731 countsByYear W20572017312021 @default.
• W2057201731 countsByYear W20572017312022 @default.
• W2057201731 countsByYear W20572017312023 @default.
• W2057201731 crossrefType "journal-article" @default.
• W2057201731 hasAuthorship W2057201731A5000750846 @default.
• W2057201731 hasAuthorship W2057201731A5006104041 @default.
• W2057201731 hasAuthorship W2057201731A5033546842 @default.
• W2057201731 hasAuthorship W2057201731A5036349678 @default.
• W2057201731 hasAuthorship W2057201731A5038307470 @default.
• W2057201731 hasAuthorship W2057201731A5042667629 @default.
• W2057201731 hasAuthorship W2057201731A5049385583 @default.
• W2057201731 hasAuthorship W2057201731A5055045706 @default.
• W2057201731 hasAuthorship W2057201731A5060055306 @default.
• W2057201731 hasAuthorship W2057201731A5061026876 @default.
• W2057201731 hasAuthorship W2057201731A5062979200 @default.
• W2057201731 hasAuthorship W2057201731A5070904381 @default.
• W2057201731 hasAuthorship W2057201731A5077963154 @default.
• W2057201731 hasAuthorship W2057201731A5090435894 @default.
• W2057201731 hasBestOaLocation W20572017312 @default.
• W2057201731 hasConcept C104317684 @default.
• W2057201731 hasConcept C121332964 @default.
• W2057201731 hasConcept C126322002 @default.
• W2057201731 hasConcept C142424586 @default.
• W2057201731 hasConcept C143998085 @default.
• W2057201731 hasConcept C150194340 @default.
• W2057201731 hasConcept C185592680 @default.
• W2057201731 hasConcept C190727270 @default.
• W2057201731 hasConcept C2776694085 @default.
• W2057201731 hasConcept C2776755627 @default.

• next